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Dr John R. Handy (Portland, Ore). I thank the Association for
the invitation to make some comments and to pose some questions.
Dr Cerfolio, your prodigious work effort always impresses a room
full of people who dedicate their lives to prodigious work efforts,
and this particular project is a tour de force in database detail and
the actual gathering of data. I do not know how you and Dr Bryant
actually pulled it off. It is the source of a fascinatingmystery tome.
When I look at these types of efforts, I find it instructive to view
them through the lens of the Donabedian formula for health care
quality as defined by the structure in which the care is rendered,
the processes of the care, and the outcomes. There is often a blur-
ring of the terminology when discussing quality or its components.
Finally, I wonder whether you have not undersold your conclu-
sions in that one very viable conclusion that you could have from
your same data is that optimal care decreased morbidity. This is
important because morbidity not only has human suffering but
also has cost implications and, frankly, in high-quality programs,
we probably have more opportunity for decreasing morbidity
than mortality.
I have 3 questions, the first of which you already mentioned. My
first question concerns the identification of your benchmarks, espe-
cially your critical versus your noncritical benchmarks, especially
vis-a-vis things for which there are very few data, such as accom-
plishing a lobectomy in less than an hour and 40minutes or a blood
loss of less than 100mL. You are in a lonely position in this nascent
field and your efforts are to be commended, but this is not a field
devoid of information. The National Surgery Quality Improvement
Program (NSQUIP), the POSSEM score (Physiologic and Opera-
tive Severity Score for Enumeration of Morbidity and Mortality),
and the Mayo Clinic, for example, in 2008 Annals of Thoracic Sur-
gery using 9 senior clinicians, including nonsurgeons such as phy-
sician’s assistants and nurses, came up with patient-centered
quality indicators for pulmonary resection. Finally, last year in
the European Journal of Cardio-Thoracic Surgery the Glenfield
Hospital group published a similar-type effort. So can you defend
your selection of these particular 55 criteria?
Dr Cerfolio. First, thank you for your kind comments. It is
a great question and the truth is that I really cannot defend them.The Journal of Thoracic and CThose were things that we believed as a team. As you said, there is
some literature out there, but not very specific nor validated bench-
marks, particularly this set of patients that we have. That is why I
list this as one of the weaknesses of the study: our benchmarks are
not validated either.
Dr Handy. Second, can we use your practice to draw conclu-
sions for the greater thoracic surgery community at large? Your
program leverages the widely described benefits for improving
outcomes, including high clinical volume, multidisciplinary
care, and specialized care. Those are really not debatable. If you
do the math, you are doing over 250 pulmonary resections for
cure annually. Boffa’s report of the general thoracic surgery data-
base in the 2008 Journal of Thoracic and Cardiovascular Surgery
is contributed to only by board-certified general thoracic surgeons.
We are performing a median of 31 pulmonary lobectomies a year.
So you are doing good things, but you are also not doing some
things that had been shown to be of benefit. In February 2010,
our 3 major journals, the Journal of Thoracic and Cardiovascular
Surgery, the Annals of Thoracic Surgery, and the European Jour-
nal of Cardio-Thoracic Surgery, showed that video-assisted
(VATS) lobectomy had less perioperative morbidity, had improved
6-month functional outcomes, and also had the same oncologic
benefit at 5 years, so VATS lobectomy is a hard thing not to
perform when you are talking about quality of care.
DrCerfolio. I agree and those are excellent points. After going to
meeting after meeting, I would be dishonest scientifically if I did not
say that I now believe that minimally invasive lobectomy, which can
be done with VATS, may decrease morbidity. However, it is the im-
proved 5-year survival of several reports that really gotme interested
in revisiting the concept of VATS, and after doing several more I
started doing robotic lobectomies.We have done 46 completely por-
tal robotic lobectomies now. It has changed my life in someway for
the worse—home later—but it has been better for my patients in
many ways. I have seen decreased morbidity doing minimally inva-
sive robotic lobectomy. I am still not a big fan ofVATS formany rea-
sons. I still see a lot of pain from camera torquing on the intercostal
nerve, probably because I have medical students most commonly
driving my camera. I run several rooms and have a different medical
student in each room who runs the camera, and as soon as they get
good they are gone 2 weeks later. With robotic lobectomy, the sur-
geon drives the camera. With our technique, the surgeon provides
the retraction using the robotic fourth arm, and the visibility, the
lymphnodedissection, and thevessel andN1dissection are unequiv-
ocally easier to dowith the robot than with VATS. It has been some-
thing that we are studying. I am a proponent of it, but I think we need
to carefully study the increased cost and the time. However, we have
seen decreased morbidity with it. It is a good point.
Dr Handy. Third, you accomplished your critical benchmarks
and decreased morbidity. What exactly is the linkage for that?
DrCerfolio.That is another great question. The real question is,
are the critical benchmarks nothing more than surrogates for
patients doing well, as I tried to allude to in the presentation? If
one benchmark is that the patients go home in 4 days, and then if
they do not hit that benchmark and it is critical, then obviously
therewas a problem. In away they are surrogates for patients doing
well, but I think there is a little bit more to it than just that. As you
say, this is an extremely complicated studywhere there are somuch
data that we are not sure if we have completely analyzed all of it allardiovascular Surgery c Volume 141, Number 1 31
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Scorrectly. I look forward to the reviewers beating it up a little bit and
chewing this out a little bit to help us make it better.
Dr Richard Whyte (Stanford, Calif). I applaud you on a great
presentation and for your continued self-examination. I have
a comment and a couple of questions.
First of all, I think that your final statement that ‘‘pay for perfor-
mance is unsupported’’ is carefully chosen wording and, perhaps,
better than calling it ‘‘unsupportable.’’ I think that was intentional.
Well done.
Dr Cerfolio. Right.
DrWhyte. I think part of that may be because quality is not just
short-term mortality, but also long-term mortality, length of stay,
cost, and, as Scott Millikan pointed out so poignantly, relationships
with the patient and his or her family. When you focus on just one
area of quality, short-term mortality, I think that you miss some of
the aspects of quality that are so important.
I have a couple of questions. First, maybe I misunderstood
things, but in your presentation you pointed out that missing major
benchmarks did not affect mortality.
Dr Cerfolio. It did not. The lack of delivery of the 10 critical
benchmarks did not negatively affect operative mortality, but it
was associated with increased major morbidity.
Dr Whyte. Okay, I was not sure. In the abstract it seemed to be
different.
Dr Cerfolio. Things have changed since the abstract was sub-
mitted because we have done so many more statistical analyses.
I cannot tell you what a pain in the neck this one has been, but
we have done a million analyses since the abstract, so some mes-
sages have changed for sure.
Dr Whyte. Last, the educational component to this: you said
97% of the time you made all your intraoperative benchmarks.
Now one of those on your list was the surgeon performing the
skin incision.
Dr Cerfolio. Yes.
Dr Whyte. How do you teach the residents, particularly when
you have chief residents, if 98% of the time you are doing the
operation from skin to skin?
Dr Cerfolio. You have misinterpreted me making the incision
versus me doing the whole case. I make the skin incision and
then I give them the Bovie instrument and have them go from there.
However, the point is I am there the entire time. I tell the patients
who come tome that I am there. I make the skin incision. I am there
for all the critical parts and really for the entire procedure, and I
hold my word to the patients. But then I usually give the resident
or the fellow the Bovie instrument as soon as I make the incision.
Dr Whyte. Interesting distinction.
Dr Cerfolio. No, I do. I make the skin incision and I am there
when the skin is closed; I am there essentially the whole time.
I may leave to do a rigid bronchoscopic procedure or a mediastino-
scopy in the middle of a robotic lobe, and I tell them that; we leave
a little extra time and use an hour and 40 minutes in there because
I leave sometimes, but I am there when the operating is being done
and for the opening and closing.
Dr Whyte. So are you serious that a major quality index is that
you, personally, make a skin incision and then hand the Bovie in-
strument to someone else to do a lot of the operation?
Dr Cerfolio. Yes. I am aware of some places where there is
some ghost surgery going on, and I know at least when I was doing32 The Journal of Thoracic and Cardiovascular Surgeit, mistakes resulting from inexperience were made. I think if you
have a senior person there taking a resident or a fellow through the
procedure, it is safer than the younger resident by himself. If the
resident or fellow does it by himself or herself, depending on the
level of experience, I think the quality of the product goes down.
Dr Whyte. I would agree with that. Thank you.
Dr Paul Schipper (Portland, Ore). I had a comment and a ques-
tion. Now I have 2 questions.
When I read through your critical benchmarks in the published
abstract, I noticed all of them with one exception were things that
happened to you—as you said, surrogates for problems that oc-
curred. The patient goes to the ICU, bleeding, transfusion. The
only one that you could affect was whether or not they got pulmo-
nary rehabilitation before the operation. In the new revised list of
critical benchmarks, which of them can we do or affect and expect
a better outcome?
Dr Cerfolio. It really gets tricky because if you talk to Ayesha
Bryant, my partner and statistician, we can only allow patients who
were eligible for a benchmark to be considered whether they got it.
In other words, smoking cessation was a benchmark, but if the pa-
tient did not smoke, he or she was not eligible to get that particular
benchmark. It gets very tricky when you look at what benchmarks
you have delivered, because you do not want to penalize yourself
for not delivering a benchmark that a particular patient was not
even eligible for. We selected cardiopulmonary rehabilitation for
selected patients, so the majority of patients who were supposed
to get it were supposed to get it for a month. However, that was
the lowest benchmark we delivered, because too often the patient
is at home watching ESPN using the television remote control sit-
ting in a recliner. He or she was not really doing the cardiopulmo-
nary rehabilitation. Some of these things go on to the patient and
patient factors.
Dr Schipper. This study shows your attention to detail and your
ability to be self-critical, but I disagree somewhat with your
conclusion about pay for performance.
Dr Cerfolio. It is easy for us to be self-critical, but go ahead.
Dr Schipper. The nationwide mortality for lobectomy is some-
where between 5% and 7%, and yours is about half of that. What
this study really represents is Team Rob Cerfolio doing all the
things that you think you ought to do versus Team Rob Cerfolio
when you stumble. Even when you stumble your outcome is better
than that national average, so why not advocate pay for perfor-
mance? You would probably get paid.
Dr Cerfolio.Well, I appreciate your saying that, but I am going
to challenge you on that.We all know that there are many series out
there, some from those in this audience, that show operative mor-
tality less than 2%. I have never been able to achieve that and I
have been doing this for 14 years. I am very disappointed about
that. There are a lot of very good surgeons in this room who
have big series with mortalities of 1.8% and 1.7%. I think with
our robotic lobectomies we may get there.
Dr Schipper. But these are from the STS database and series
out of Memorial Sloan Kettering. They are the cream of the
crop, not the true national average.
Dr Cerfolio. You are right, but I think the minimally invasive
technique, as much as I have been a very loud voice against it,
may be able to decrease some of the mortality and the morbidity.
Some of it is patient selection, but some of it is some of these otherry c January 2011
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Sfactors we have talked about, so we are going to see. We are
halfway to 100 robotic lobectomies, and we will see where we
are. So far, we have had no mortalities and the morbidity has
been less.
Dr Scott Rankin (Nashville, Tenn). Congratulations on a very
interesting approach. I would like to make one small methodologic
comment about this paper and also Dr Grossi’s paper. A principle
of biostatistics is that 10 events should be available for every vari-
able tested in a multivariable analysis. Without that, we have the
potential for over-fitting. I am concerned that with the small num-
ber of events, testing so many variables represents over-fitting in
the multivariable analysis.
Dr Cerfolio. That is a very good point. Dr Bryant and I have
talked about that very fact as well. You asked whether it is a mys-Patient Demograph
Survey Number ______________________ D
What state do you live in? ______________ W
Have you ever smoked tobacco?     Yes No
If yes, what kind of cigarette did you smoke most o
How many packs per day did you smoke?  ______
When was your last cigarette?  _______________
What is your job (if retired, what was your job before retire
How many other people live in your home (not counting yo
How long ago did your primary doctor refer you to see Dr. 
How many times each year do you see your primary care 
ob/gyn, internest)? ______________
What is the highest level of education that you completed?
Less than 8th grade Some high schoo
Trade school/technical Some college wo
Some graduate work Graduate degree
What is your household income per year (average of the la
Less than $15,000/year $15,001-25,000
$50,001-75,000 $75,001-100,000
APPENDIX 1. Survey giv
The Journal of Thoracic and Ctery how we do these. Well, it is not a mystery. We have constant
communication. Many times she hates me and sometimes I get
tired of her because we are always talking about our studies every
single day.
I dowant to make 1 last comment. I was talking about quality of
care and patient satisfaction. We heard earlier today from our pres-
ident that ‘‘hope is the currency of the waiting room.’’ I think he is
exactly right. We need more benchmarks that look at patient and
family satisfaction, not just surgical intraoperative benchmarks.
That is why I have so many of these in this paper. We may even
need more, because that is really how we are measured, not just
our outcomes but what the family perceives of the product we
have delivered, even when the end result is not the one we were
praying for preoperatively.ic Survey
ate:__________________________
hat is your zip code? ____________
ften?  Menthylated    Non-menthylated  Other           
How many years have/did you smoke? ______  
____
ment)?
urself)? __________
Cerfolio? ___________________
physician (for example: your family doctor, your 
  
l Graduated high school
rk Graduated college with degree
 (MS) Graduate degree (doctorate)
st 10 years)?
$25,001-50,000
$100,001 or more
en in clinic to patients
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